Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Ramalingam, Suresh S.; Zhou, Caicun; Kim, Tae Min; Kim, Sang-We; Yang, James Chih-Hsin; Riely, Gregory J.; Mekhail, Tarek; Nguyen, Danny; Campelo, Maria Rosario Garcia; Felip, Enriqueta; Vincent, Sylvie; Jin, Shu; Bunn, Veronica; Lin, Jianchang; Lin, Huamao Mark; Mehta, Minal; Janne, Pasi A.

Publication Date

  • May 20, 2021

webpage

published in

category

volume

  • 39

issue

  • 15